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Aims of the study: The aim of this retrospective study was to appraise the impact of central neck
dissection (CND) when treating papillary thyroid carcinoma (PTC) and identifying predictors of tumour
recurrence by analysing the results and complications related to this surgical procedure.
Materials and methods: The study examined the histories of 347 patients with PTC, divided into two
groups: group A including 284 patients who underwent total thyroidectomy (TT) only; group B including
63 patients who underwent TT and CND and possible lateral neck dissection (LND).
Results: The patients in the B group were younger than those in the A group (an average of 44.5 vs. 48.6;
p ¼ 0.03) and their tumours were larger (1.91 cm vs 1.27 cm, p ¼ 0.001). Multifocality, extra-capsular
extensions of the neoplastic mass and high cell histological variant were more prevalent in the B
group. The incidence of permanent hyperparathyroidismwas higher in group B than in group A (25.4% vs
9.5%, p ¼ 0.0006). Recurrence of disease and the numbers requiring reoperation were also higher in
group B: (24.1% in group B vs 6.6 in group A, p < 0.0001). Patients classiﬁed as clinically N0 at their ﬁrst
operation and who were most probably clinically N1, totalled 6.6%.
Conclusions: Our data show that only extra-capsular extension may be considered a predictor of recur-
rence. The ﬁndings of our study support the idea of carrying out “therapeutic” CND only in cases of
preoperative or macroscopic intraoperative clinical evidence of lymph-node involvement.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Papillary thyroid carcinoma (PTC) accounts for about 80% of all
thyroid cancers and is the sixth most common cancer with an
increased incidence in the case of females [1]. PTC presents a high
incidence of lymph-node metastases, particularly in the central
compartment (level VI). The presence of clinically evident lymph-
node metastases in the central compartment requires, besides to-
tal thyroidectomy (TT), also central neck dissection (CND). CND
carried out (clinically or availing of radiology) to remove apparent
metastatic lymph-nodes in the central compartment (cN1a) is
called “therapeutic central neck dissection” while central lympha-
denectomy performed in the absence of suspected lymph-nodeRome, Italy.
. Tartaglia).
by Elsevier Ltd. All rights reservedmetastases (cN0) is deﬁned “prophylactic” or “elective” [2]. In the
presence of cN1a carcinomas, almost all agree in associating ther-
apeutic CND and TT, whereas in the case of cN0, and, therefore, for
“prophylactic” CND the issue is quite controversial. Many factors
should be consideredwhen decidingwhether andwhen to perform
prophylactic CND: the T of the tumour, gender, age, histological
subtype, the involvement of the capsule and so on. Personal
conviction is supported by rates of reoperation due to recurrence,
survival over time, laboratory index trends. Unfortunately, there
isn't any decisive contribution to the discussion due to the lack of
randomized prospective trials and the explanations of this lack
have been explained quite thoroughly in a recent article regarding
this issue [3]. Therefore, we wish to make a contribution by
expounding our convictions starting from our personal experience.
The purpose of this retrospective study was, therefore, to assess the
impact of the CND in the treatment of PTC's by identifying factors
predicting tumour recurrence and analysing the oncological results
and complications related to the surgical procedure..
Table 1
Demographic data.
Variables Group A
(N ¼ 284)
Group B
(N ¼ 63)
Odds ratio B/A P value
Age (in years) 48.6 ± 13.7 44.5 ± 15.4 _ 0.03
Male % 59 (20.8) 16 (25.4) 0.8 0.4
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This retrospective study was carried out by examining the case
histories of patients who underwent thyroid surgery in the years
between 2000 and 2010 at the Department of Surgical Sciences of
“Sapienza” University of Rome. We included all patients with his-
tologicalepathological PTC diagnoses. We excluded from the study
all patients who had undergone surgery for benign thyroid disease,
surgery for non-papillary thyroid carcinomas, previous radiation
therapy of the neck, simultaneous surgery for hyperparathyroid-
ism, completion thyroidectomy. The patients were divided into two
groups. The ﬁrst group (group A) included all patients with clini-
cally negative lymph nodes (cN0) who underwent TT. The second
group (group B) included all patients who underwent TT and CND
and/or lateral neck dissection (LND) with preoperative or intra-
operative clinical evidence of lymph-node metastases both in the
central and lateral cervical compartments (cN1a and cN1b). Pre-
operative assessment was carried out by clinical examination, ul-
trasound exam of the neck, ﬁne needle aspiration, measurements of
serum calcium, phosphorus, PTHi, Tg, anti-Tg antibodies. The
motility of the vocal cords was assessed by preoperative and
postoperative indirect or ﬁbre optics laryngoscopy. Temporary
recurrent laryngeal nerve dysfunction was deﬁned as decreased or
absent vocal cord mobility resolving within 6 months of surgery.
Permanent recurrent nerve paralysis was deﬁned as vocal cord
dysfunction persisting beyond 6 months after initial surgery.
Temporary hypocalcaemia was deﬁned as a decrease in serum
calcium levels of <8.0 mg/dl. Deﬁnitive hypoparathyroidism was
deﬁned as the presence of intact PTH values of <10 pg/ml persisting
one year after surgery. Phosphorus concentrations were evaluated
only after ruling out any concomitant causes of hyper-or hypo-
phosphatemia that might invalidate the assessment [4]. All patients
were subjected to whole-body scintigraphy after surgery and/or
radioiodine ablation therapy according to the ATA guidelines of
2009. All the patients data gathered over the years were entered
into a database. The data included the demographic characteristics
of the patients, the histologicalepathological features of their pri-
mary tumours and lymph nodes and postoperative complications
The follow up of all the patients was carried out by monitoring
serum thyroglobulin, anti-thyroglobulin antibodies, serum calcium,
phosphorus and iPTH, annual neck ultrasonography, total body
scintigraphy. Data regarding the number of reoperations were also
collected and these were classiﬁed according to the lymph node
compartment removed: central (level VI), lateral (levels IeIV), both
(levels IeVI). Recurrence of neoplastic disease was deﬁned as the
presence of neoplastic disease 6 months after the ﬁrst surgical
operation.
Statistical analyses were carried out using SAS 6.1 software. The
quantitative variables were expressed as ±SD averages and quali-
tative variables as proportions and percentages. The Student's t-test
and the ManneWhitney U-test were used to compare quantitative
variables, respectively, with or without normal distribution. The
chi-square test was used to investigate differences between quali-
tative variables. The value of p < 0.05 was considered signiﬁcant.
The analysis of variance was performed to determine whether
gender, age 45, high cell variant, multifocality, extra-capsular
extension, hyperfunction, tumour size 1 cm and chronic
thyroiditis may be considered predictors of tumour recurrence.Female % 225 (79.2) 47 (74.6) 1
Tumour Size (mm) 1.27 ± 1.4 1.9 ± 1.16 _ 0.001
Tumour multifocality % 69 (24.3) 29 (46.0) 1.9 0.0005
Extra-thyroidal extension % 52 (18.3) 35 (55.6) 3.0 0.0001
Hyperthyroidism % 18 (6.3) 1 (1.6) 0.2 0.13
Hashimoto thyroiditis % 62 (21.9%) 8 (12.7%) 0.6 0.09
N ¼ numbers of subjects. Age and tumour size are expressed as means ± standard
deviations.3. Results
Three hundred and forty-seven patients fulﬁlled the study's
inclusion criteria. Group A included 284 patients, who underwent
TT only. Group B included 63 patients who underwent both TT andCND and in some cases LND too. A summary of the demographic
and clinical characteristics of the two groups is provided in Table 1.
The patients in group B were younger on average than those in
group A (average age of 44.5 vs. 48.6, p ¼ 0.03). The gender dis-
tribution rate was similar for both groups. Two hundred and eight
subjects underwent preoperative cytology (Table 2). The sizes of
the tumours were greater in group B compared to group A (1.91 cm
vs. 1.27 cm, p ¼ 0.001). Multifocality and extra-capsular extension
of the tumour occurred signiﬁcantly more frequently in group B.
The higher frequency of extra-capsular extension and larger
tumour size in the group B was proved by the greater frequency of
cases rated pT3, and pT4 in group B (respectively 17.2% vs 34.9% and
5.6% vs 19%, p < 0.0001) (Table 3). Lymphocytic thyroiditis was
apparently more frequent in group A than in group B (21.9% vs
12.7%), but again the statistical signiﬁcance was low (p ¼ 0.09). A
summary of histological variants distribution between the two
groups are provided in Table 4. The most frequent and classical
histological variant was practically the same in both groups and
was, therefore, statistically insigniﬁcant: 60.5% in group A vs 60.3%
in group B (p¼ 0.97). A high cell variant ratewas prevalent in group
B: 7.9% vs. 2.46% (p ¼ 0.03). The follicular variant was slightly more
frequent in group A (23.9% vs 15.9%) andwas statistically signiﬁcant
(p ¼ 0.16).
A summary of the postoperative complications for both groups
is provided in Table 5. Bleeding requiring reoperation occurred only
in group A and in 5 patients only (1.76%). In the case of the entire
sample, transient recurrent lesion occurred in 4.9% instances and
proved deﬁnitive in 2.6% cases. The average values for serum cal-
cium and phosphorus during the ﬁrst and second days and one year
after surgery, as well as the mean values for iPTH one year after
surgery are provided in Table 6. Occurrence of transient hypo-
calcaemia does not differ signiﬁcantly between group A and group
B (10.9% vs. 12.7%, respectively, p ¼ 0.6) although the mean values
for serum calcium during the ﬁrst and second postoperative days
are lower for group B (8.1 mg/dl vs 7.8 mg/dl, p ¼ 0.007). All the
patients in our sample had normal preoperative phosphorus levels,
which mean that any early and late postoperative changes could
reasonably be considered as side-effects of surgery. No statistically
signiﬁcant results emerged from the data analysed, with the
exception of the one-year phosphorus concentrations in the
symptomatic patients. The cumulative incidence of deﬁnitive hy-
poparathyroidism in the entire sample was 12.4%, but revealed a
higher prevalence in group B than in group A (25.4% vs 9.5%,
p ¼ 0.0006). The average values for iPTH a year after surgery were
lower in group B than in group A (24.08 pg/ml vs 33.3 pg/ml,
p < 0.0001). The presence of parathyroid during ﬁnal histological
examinations was shown to be more frequent in group B than in
group A (19.7% vs. 14.7%, p ¼ 0.18). In the B group the parathyroid
was never replanted, in group A at least one parathyroid gland was
replanted (in 12 cases). The average values for thyroglobulin and
Table 2
Preoperative cytological diagnosis.
Preoperative cytology Group A (N ¼ 162) Group B (N ¼ 46) P value
Thy 1% 5 (3.1) 0 (0) 0.22
Thy 2% 30 (20.5) 1 (2.2) 0.03
Thy 3% 30 (18.5) 2 (4.3) 0.019
Thy 4% 90 (55.6) 26 (56.5) 0.85
Thy 5% 7 (4.3) 17 (36.9) 0.0001
Distribution of preoperative cytological features for the two groups.
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up, measured during the preoperative phase, and after initial
postoperative ablation, at one year and 5 years after surgery, are
shown in Table 7. The data show average values of post-operative
thyroglobulin to be higher in group B than in to group A (29.08
vs 21.05 ng/ml, p ¼ 0.001). The data show that average post-
operative thyroglobulin values were higher in the B group than in
the A group (29.08 vs 21.05 ng/ml, p¼ 0.001). The average values of
thyroglobulin after initial ablative treatment did not differ signiﬁ-
cantly while one year after surgery thyroglobulin values were lower
in group A than in group B (0.85 vs 1.4 ng/ml). Five years after
surgery, a follow-up involving 226 people from the A group and 62
patients belonging to the B group was carried out. There weren't
any signiﬁcant differences in average thyroglobulin values for both
groups, which in both cases was <1 ng/ml.
Recurrent disease requiring reoperation occurred more
frequently in group B : 24.1% in group B vs 6.6% in group A,
p < 0.0001. Therefore, the percentage of patients clinically N0 at the
time of the ﬁrst surgical treatment whowere probably N1was 6.6%.
The two groups were signiﬁcantly different in the type of reoper-
ations performed: in group B, LND was performed in 12 patients
who had been previously subjected to TT and CND (19.3% vs 0.3%)
and in two cases there was also removal of locally relapsed
neoplastic tissue (Table 8). Reoperation was performed in the ﬁrst
group after 34.08 ± 7.6 months, in the second group 20.75 ± 5.2
months. The average number of positive lymph nodes in the ﬁrst
groupwas 13.81 ± 0.33, in the second group 13.79 ± 3.17. The size of
the tumour was signiﬁcantly related to the probability of devel-
oping recurrent neoplastic disease when measuring more than
1 cm (p ¼ 0.004).
Variance analysis was carried out to determine whether gender,
age 45 years, the high cell variance, multifocality, extra-capsular
extension, hyper-function, tumour size 1 cm, lymphocytic
thyroiditis may be considered as being predictors of lymph-node
cancer recurrence. Our data show that only extra-capsular exten-
sion may be considered as a predictor of relapse, while in the case
of men the correlation is minimal (Table 9).4. Discussion
Indications for lymphadenectomy “on principle” or “necessary”
in the treatment of PTC are the subject of lively debate in literature.
Several authors wrote of their experiences but there isn't any
prospective randomized trial decisive contribution to the discus-
sion [3]. Indication for prophylactic CND in cN0 appears to be
correlated with incidences of postoperative complications. Dralle
reports a signiﬁcant risk of postoperative hypoparathyroidism after
CND [5], but suggests that prophylactic central lymph node
dissection improves prognosis for papillary thyroid cancer [6]. Ac-
cording to Mazzaferri the incidence of transient hypoparathyroid-
ism after CND ranges between 14% and 44% [7]. For White the rate
of permanent hypoparathyroidism after total thyroidectomy with
prophylactic CND is between 0% and 14.3% [8], notwithstanding the
application of correct surgical techniques providing for recognitionand conservation of the entire cervical parathyroid [9]. Our data
don't show any signiﬁcant difference in incidences of transient
symptomatic hypocalcaemia between the two groups although the
average values for serum calcium on the ﬁrst and second post-
operative days were lower in the group B (8.1 mg/dl vs 7.8 mg/dl,
p ¼ 0.007). It appears that phosphorus ﬁnds it difﬁcult to return to
preoperative values in patients who develop postoperative hypo-
calcaemia symptoms and may therefore be considered a more
sensitive parameter in long-term follow-up. In our experience,
incidence of permanent hypoparathyroidism for the entire sample
studied was similar to the data provided by literature (about 12.4%),
but there was a higher prevalence in the group that underwent
CND. In addition, the average values for iPTH a year after surgery
were higher in the group submitted to total thyroidectomy only
(33.3 pg/ml vs 24.08 pg/ml, p < 0.0001).
Many studies showed an increased risk of recurrent paralysis in
patients undergoing CND, with rates of recurrent lesions ranging
between 1% and 12% [10]. Pereira reports increments from 3% to 6%
of recurrent lesions between TT only and TT þ CND [11]. Segal et al.
reported a higher rate of permanent nerve injury (5.8% versus 25%)
for second surgery compared to ﬁrst operations (5.8% versus 25%)
[12]. According to Popadich, the percentage of recurrent transient
paralysis increased from 1.8% after TT to 2.3% after TT þ CND,
whereas the deﬁnitive rates range from 0.4% to 1.8% [13]. For
Giordano transitional cases range from 3.6% to 5.5%, the deﬁnitive
from 1% to 2.3% [14]. In our experience, there was no signiﬁcant
difference between the two groups.
The disease recurrence rate was the subject of many studies
reported in literature. Patients with locally advanced disease have a
greater risk of relapse even if they don't have clinically evident
cervical lymph-node metastases. Unlike patients with small tu-
mours, high rates of recurrence risk depend essentially by the
initial N stage: if the risk of recurrence in N0 patients is low, N1a or
N1b present a high risk recurrence level [15,16]. Some authors
report a recurrence risk rate ranging from 0% to 9% for clinically N0
PTC patients [17], others report a probability <5% recurrence for
PTC cN0 patients or those with micro-metastases (metastases
<0.2 cm in a lymph node) [18] In our experience, evidence of
neoplastic disease recurrence was more frequent in the group
receiving CND than in the group receiving TT only (24.1% vs 6.6%,
p < 0.0001). Furthermore, surgical procedure most frequently
applied to group B was LND. So, the percentage of clinical N0 pa-
tients who was probably N1 at the time of the ﬁrst surgery was
6.6%. Reoperationwas performed in the ﬁrst group after 34.08 ± 7.6
months, in the second after 20.75 ± 5.2 months. Our ﬁnding is in
keeping with the literature as the majority of reoperations occurs
within the ﬁrst three years of follow-up.
The core issue is the downstaging of cN0 patients. One of the
main objectives of prophylactic CND in patients with small tumours
is to provide accurate staging of the disease (N0 or N1a) in order to
choose which patients require postoperative radioiodine treatment
[19]. To this end, in our experience, the method of the “sentinel”
[20] lymph-node method proved of little avail also because of the
well-known skip metastasis phenomenon. On the contrary, in the
case of patients with locally advanced tumours, the main aim of
prophylactic CND is to eliminate any residual disease from the
central compartment in order to improve the effectiveness of
postoperative therapy with radioactive iodine. In our experience,
about 6.6% of PTC patients was downstaged at the time of ﬁrst
surgery, a percentage lower compared to that reported in literature
which is about 30% [21,22]. Moreover, all patients who underwent
to second surgery were ﬁnally free from disease.
Another crucial controversy regards the size of tumour. Dralle
support the use of routine central lymph-node dissection for PTC
>10 mm in diameter [6]. Kutler and colleagues [23] in a
Table 3
T stage in groups A and B.
T stage Group A
N ¼ 284
Group B
N ¼ 63
Odds ratio
B/A
P value
pT1a % 150 (52.8) 8 (12.7) 0.24 0.0001
pT1b % 47 (16.55) 15 (23.8) 1.24 0.17
pT2 % 20 (7) 6 (9.5) 1.28 0.49
pT3 % 50 (17.6) 22 (34.9) 2 0.002
pT4 % 17 (5.6) 12 (19.0) 3.8 0.001
Table 5
Complications.
Complications Group A
(N ¼ 284)
Group B
(N ¼ 63)
Odds
ratio B/A
P value
Postoperative temporary
hypocalcaemia
31 (10.9) 8 (12.7) 1.2 0.6
Permanent hyperparathyroidism 27 (9.5) 16 (25.4) 2.8 0.0006
Postoperative temporary
vocal cord palsy
13 (4.6) 4 (6.3) 1.4 0.5
Postoperative permanent
vocal cord palsy
8 (2.8) 1 (1.6) 0.5 0.6
Seroma 9 (3.1) 0 (0) e 0.15
Haemorrhage 5 (1.7) 0 (0) e 0.06
Parathyroid glands in the specimen 42 (14.7) 12 (19.7) 4.5 0.18
Parathyroid glands transplanted 12 (4.23) 0 (0) e 0.7
Table 6
Average values for serum calcium, phosphorus, intact PTH.
Variables Group A (N ¼ 284) Group B (N ¼ 63) P value
Serum calcium 1d 8.07 ± 0.68 7.81 ± 0.65 0.007
F. Tartaglia et al. / International Journal of Surgery 12 (2014) S57eS62S60retrospective study of 83 subjects revealed no statistically signiﬁ-
cant difference regarding the risk ofmetastatic spread to the central
compartment between patients with microcarcinomas and pa-
tients with tumours larger than 1 cm. Furthermore, this study
showed that even microcarcinomas <5 mm might be associated
with an 18.8% incidence of metastatic disease. In fact, recurrence
rate was 4.8% despite the CND and the post-operative radioactive
iodine treatment. Data conﬂicting with this study were reported by
Teixeira and colleagues [24] who declare the absence of nodal
micro metastases in patients with PTC's diameter <0.5 cm. Wada
evaluated prophylactic CND useless in papillary thyroid micro-
carcinomas without palpable lymphadenopathy [25]. The different
positions about the opportunity of performing CND in patients with
tumours <1 cm led some authors to propose CND hemicompart-
ment, ipsi-lateral to the tumour, believing that reduction of the
CND extent could decrease postoperative complications. In our
experience, the univariate statistical test correlated signiﬁcantly
the size of the tumour >1 cm to the likelihood of developing
recurrent neoplastic disease (p ¼ 0.004).
Other factors being implicated in the indications for prophy-
lactic CND are gender, age, multifocality, extra-capsular invasion of
the tumour and histological type. The data in literature regarding
age and gender are conﬂicting, some authors didn't report any
statistically signiﬁcant differences between males and females [26]
although some studies stated that risk of recurrence disease in men
was greater than women [27,28.] Some authors consider age <45
years a risk factor, others hold that the risk increases in patients
45 years [28e30]. Multifocality and extra-thyroidal extension
were associated with an increased risk of lymphatic metastasis
including the laterocervical area [28,31] and a higher mortality rate
and neoplastic relapse [32]. The risk of tumour recurrence varies in
the case of multifocality from 1% to 2% in unicentric papillary micro
carcinoma, 4e6% in multifocal papillary micro-carcinoma [33,34],
8e10% in >4 cm intra-thyroidal PTC [35]. In our study, analysis of
variance revealed that only extra-capsular extension may be
considered a predictor of relapse. It is important to refer to
aggressive variants of papillary carcinoma and, in particular, to
high-cell and diffused-sclerosis carcinomas. Some variants of
papillary carcinoma present more aggressive pathological features,
as extra-capsular spread and lymph node metastases. TT and CND
treatment might be warranted if the diagnosis were made pre-or
intraoperatively [36]. In this study the most common histological
variant was the classic one, equally distributed in both groups andTable 4
Distribution of histological variants of papillary carcinoma of the thyroid.
Variant Group A
(N ¼ 284)
Group B
(N ¼ 63)
Odds ratio B/A P value
Classic variant % 172 (60.5) 38 (60.3) 1.1 0.97
Tall cell-variant % 7 (2.46) 5 (7.9) 3.2 0.03
Follicular variant % 68 (23.9) 10 (15.9) 0.65 0.16
Diffuse sclerosing
variant %
29 (10.2) 7 (11.1) 1.1 0.6
Insular variant % 8 (2.8) 3 (4.7) 1.4 0.4without any signiﬁcant statistical difference: 60.5% in group A vs
60.3% in group B (p ¼ 0.97). The high-cell variant was prevalent in
group B: 7.9% vs. 2.46% (p ¼ 0.03). The follicular type was more
frequent in group A (23.9% vs 15.9%), but did not reach statistical
signiﬁcance (p ¼ 0.16). Furthermore the familial nonmedullary
thyroid carcinomas (FNMTC) have an increased risk of multifocal
disease and lymph node involvement with higher recurrence rates
and decreased disease-speciﬁc survival rates [37]. Moreover some
Authors have shown the correlation between the presence of a
BRAF-V600 mutation and the incidence of central compartment
lymph node metastasis [38].
In the follow up of PTC a crucial role is played by thyroglobulin
measurements. Because thyroglobulin is produced only by follic-
ular cells, after surgery it unequivocally indicates persistent dis-
ease, and should lead to further tests aimed to discover the lesion
producing it [39e45]. On the contrary, if there are no detectable
serum thyroglobulin levels, the patient may be considered in clin-
ical remission [46]. In our study, the average Tg values were higher
in the group that underwent CND (29.08 vs. 21.05 ng/ml, p¼ 0.001).
One year after surgery, thyroglobulin values were lower for group A
than for group B (0.85 vs 1.4 ng/ml). The 5-year follow-up was
completed by 226 patients in group A and 62 patients in group B.
There were no signiﬁcant differences in average thyroglobulin
values between the groups, both of which yielded values of <1 ng/
ml. Thyroglobulin is, in our opinion, a reliable marker of disease
recurrence with higher average values for group B, where recur-
rence rate was higher.5. Conclusions
Our retrospective study shows that the 6.6% of patients staged as
clinically N0 was really N1 at the time of ﬁrst surgery. This meansSerum calcium 2d 8.1 ± 0.75 7.84 ± 0.68 0.003
Serum calcium 1y 8.8 ± 0.36 8.7 ± 0.36 0.31
Phosphorus 1d 3.8 ± 0.66 4.1 ± 0.78 0.01
Phosphorus 2d 4.05 ± 1.8 3.9 ± 0.69 0.67
Phosphorus 1y 4.2 ± 0.39 4.4 ± 0.39 <0.0001
PTH 1y 33.06 ± 16.78 24.08 ± 16.66 <0.0001
The values are presented as mean ± Std. Dev. Serum calcium 1d ¼ mean values for
serum calcium on postoperative day 1. Serum calcium 2d ¼ mean values for serum
calcium on postoperative day 2. Serum calcium 1y ¼mean values for serum calcium
a year after surgery. Fosforo1d ¼ average values for phosphorus on postoperative
day 1. Phosphorus 2d ¼ average values of phosphorus on postoperative day 2.
Phosphorus 1y ¼ average values for serum phosphate one year after surgery. PTH
1y ¼ average values for intact parathyroid hormone one year after surgery.
Table 7
Average thyroglobulin (ng/ml) and anti-tyroglobulin antibody values (IU/ml).
Variables Group A (N ¼ 284) Group B (N ¼ 63) P value
Preop Tg 21.5 ± 22.05 29.08 ± 15.46 0.001
Pre-ablation Tg 1.98 ± 0.85 1.97 ± 0.97 0.9
Tg 1y 0.85 ± 0.95 1.4 ± 0.85 <0.0001
Preop. Anti-Tg 37.82 ± 63.13 38.25 ± 16.43 0.9
3 months Anti-Tg 14.68 ± 10.8 14.14 ± 8.38 0.6
Anti-Tg 1y 10.57 ± 7.38 9.33 ± 14.49 0.51
Variables Group A (N ¼ 224) Group B (N ¼ 62) P value
Tg 5y 0.11 ± 0.84 0.12 ± 0.07 0.46
Anti Tg 5y 5.01 ± 7.28 3.11 ± 5.44 0.025
Tg 1y ¼ average values for thyroglobulin one year after surgery. Anti-Tg 1y ¼mean
values of anti-thyroglobulin one year after surgery. Tg 5y ¼ average values of
thyroglobulin 5 years after surgery. Anti-Tg 5y ¼ average values of thyroglobulin 5
years after surgery. Data are expressed as mean ± Std. Dev.
Table 8
Disease recurrence requiring reoperation.
Group A (N ¼ 289) Group B (N ¼ 63) P value
Reoperation 19 (6.6%) 14 (24.1%) <0.001
Mean time to
reoperation (months)
34.08 ± 7.6 20.75 ± 5.2 0.0002
CND 12 (4.2%) 0 (0%) 0.1
LND 1 (0.3%) 12 (19.3%) <0.0001
CND þ LND 6 (2.11%) 1 (1.61%) 0.8
Removal of local recurrence 0 2 (3.23%) 0.002
Mean no. positive nodes 0.33 ± 13.81 3.17 ± 13.79 <0.001
The average reoperation time-lapse and the average number of positive lymph
nodes expressed as mean ± Std. Dev. CND ¼ central neck dissection. LND ¼ lateral
neck dissection.
Table 9
Variance analysis factors inﬂuencing disease recurrence rates.
Variable DF Parameter
estimate
Standard
error
T value Pr < (t)
Gender 1 0.09 0.04 2.31 0.021
Variant 1 0.19 0.09 2.12 0.03
Tumour multifocality 1 0.04 0.03 1.14 0.25
Extra-thyroidal extension 1 0.18 0.04 4.61 <0.0001
Hyperthyroidism 1 0.031 0.07 0.43 0.66
Patient age (45 years) 1 0.017 0.03 0.52 0.62
Hashimoto thyroiditis 1 0.003 0.04 0.52 0.6
Tumour size (1 cm) 1 0.03 0.03 0.96 0.33
F. Tartaglia et al. / International Journal of Surgery 12 (2014) S57eS62 S61that, according to our samples, a 6.6% of the PTC patients at the time
of ﬁrst surgery were probably downstaged, but this percentage is
lower than that reported in literature, that is about 30%. Moreover,
patients who underwent to second surgical treatment for recurrent
tumour were ﬁnally free of disease at follow up.
Our ﬁndings support the idea of carrying out “therapeutic” CND
only in the presence of clinical evidence of preoperative or intra-
operative macroscopic lymph node involvement. We also believe
that level VI is an anatomical functional whole and that central
hemicompartment lymphadenectomy is not oncologically correct.
Prophylactic CND should be taken into account in case preop-
erative tests rate tumours T3 and T4. We don't consider gender or
age 45 discriminatory factors for prophylactic CND since our data
are discordant with those of literature.Ethical approval
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